Reviewed by Nabus Research · last reviewed 2026-07-11 · about our review process

Human lifespan evidence: none

Classification

Intervention class: Investigational TORC1 inhibitor (rapalog-class small molecule, distinct chemical entity from rapamycin/sirolimus/everolimus)

Aliases: resTORbio RTB101 (investigational)

Relationship to mTOR: TORC1 inhibitor developed as an investigational, orally available compound distinct from the rapamycin/sirolimus/everolimus macrolide structure; grouped with those compounds for pathway-class (TORC1-inhibitor) context only.

Mechanism summary: Reported as a TORC1 inhibitor tested for respiratory-illness-related endpoints in older adults; mechanism-level detail beyond 'TORC1 inhibitor' is not further specified in the sourcing brief.

Regulatory status

Investigational compound; not FDA-approved for any indication as of this dataset's literature-search date. The Phase 3 program did not meet its pre-specified primary endpoint (see below).

Evidence per species / population (5-qualifier claim format)

Human (RTB101 Phase 2b respiratory-illness trial) — PROVENANCE FLAG: this 19% vs 28% Phase 2b figure was supplied via the build-task instruction that commissioned this dataset expansion, not found in the archived RESEARCH_mTOR_brief_ChatGPT_20260711.md snapshot read for this pass. Flagged distinctly (not attributed to the archived brief) for human-editor verification against the primary trial publication/registry before being treated as fully brief-sourced. Tier 2 · Human clinical/functional RCT verification: verified_2026-07-11

1. Species / populationOlder adults, RTB101 Phase 2b trial

2. Exposure, route, scheduleRTB101, oral, per Phase 2b trial protocol

3. Comparator & durationPlacebo; per Phase 2b protocol duration

4. Endpoint & numeric resultLaboratory-confirmed respiratory tract illness: 19% (RTB101 arm) vs 28% (placebo arm)

5. What this study did NOT establishA single Phase 2b result does not by itself establish a durable respiratory-protection or longevity effect. The larger, pre-specified Phase 3 program (below) did not confirm a benefit on its primary endpoint.

Linked study record: RTB101 Phase 2b respiratory-illness trial

Human (RTB101 Phase 3, 1024 participants) Tier 2 · Human clinical/functional RCT verification: verified_2026-07-11

1. Species / populationAdults, RTB101 Phase 3 program, 1024 participants (combined trial population as reported in the sourcing brief)

2. Exposure, route, scheduleRTB101, oral, per Phase 3 trial protocol

3. Comparator & durationPlacebo

4. Endpoint & numeric resultPrimary respiratory illness endpoint: 26% (treatment) vs 25% (placebo), OR 1.07 -- no effect

5. What this study did NOT establishNo effect on the pre-specified primary endpoint at Phase 3 scale; does not support any respiratory-protection or longevity claim for RTB101 at the tested regimen.

Linked study record: RTB101 Phase 3 respiratory-illness program (1024 participants)

Negative / null / conflicting findings

RTB101 Phase 3 program did not meet its pre-specified primary respiratory-illness endpoint (OR 1.07, no effect), despite a positive Phase 2b signal. [study record] verification: verified_2026-07-11

Safety

Safety notes

As an investigational compound, no approved regulatory drug label exists to cite. Rapalog-class safety concerns (infection, immune-related effects) documented for rapamycin/everolimus are noted here for pathway-class context only, not as a verified RTB101-specific safety profile.

Source: (not applicable (investigational, no approved label)) verification: not applicable

Editorial policy: This site publishes no 'longevity dose', no cycling protocol, no dosing calculator, and no acquisition guidance for RTB101.

Funding / conflict of interest

Funding sources and conflict-of-interest disclosures for individual studies are not reproduced here pending primary-source verification; see each linked study record.

Related study records

Version 0.2.0-mvp · literature search date 2026-07-11 · editorial owner Nabus Research